These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 17937915)

  • 1. Partial agonists activate PPARgamma using a helix 12 independent mechanism.
    Bruning JB; Chalmers MJ; Prasad S; Busby SA; Kamenecka TM; He Y; Nettles KW; Griffin PR
    Structure; 2007 Oct; 15(10):1258-71. PubMed ID: 17937915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
    Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
    J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
    Hamuro Y; Coales SJ; Morrow JA; Molnar KS; Tuske SJ; Southern MR; Griffin PR
    Protein Sci; 2006 Aug; 15(8):1883-92. PubMed ID: 16823031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
    Sheu SH; Kaya T; Waxman DJ; Vajda S
    Biochemistry; 2005 Feb; 44(4):1193-209. PubMed ID: 15667213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
    Lu IL; Huang CF; Peng YH; Lin YT; Hsieh HP; Chen CT; Lien TW; Lee HJ; Mahindroo N; Prakash E; Yueh A; Chen HY; Goparaju CM; Chen X; Liao CC; Chao YS; Hsu JT; Wu SY
    J Med Chem; 2006 May; 49(9):2703-12. PubMed ID: 16640330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein polarization is critical to stabilizing AF-2 and helix-2' domains in ligand binding to PPAR-gamma.
    Ji CG; Zhang JZ
    J Am Chem Soc; 2008 Dec; 130(50):17129-33. PubMed ID: 19007119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomic structure of mutant PPARgamma LBD complexed with 15d-PGJ2: novel modulation mechanism of PPARgamma/RXRalpha function by covalently bound ligands.
    Waku T; Shiraki T; Oyama T; Morikawa K
    FEBS Lett; 2009 Jan; 583(2):320-4. PubMed ID: 19101554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry.
    Chalmers MJ; Busby SA; Pascal BD; He Y; Hendrickson CL; Marshall AG; Griffin PR
    Anal Chem; 2006 Feb; 78(4):1005-14. PubMed ID: 16478090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation.
    Ye F; Zhang ZS; Luo HB; Shen JH; Chen KX; Shen X; Jiang HL
    Chembiochem; 2006 Jan; 7(1):74-82. PubMed ID: 16317783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
    Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
    J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.
    Einstein M; Akiyama TE; Castriota GA; Wang CF; McKeever B; Mosley RT; Becker JW; Moller DE; Meinke PT; Wood HB; Berger JP
    Mol Pharmacol; 2008 Jan; 73(1):62-74. PubMed ID: 17940191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma.
    Gani OA; Sylte I
    Chem Biol Drug Des; 2008 Jul; 72(1):50-7. PubMed ID: 18554251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
    Itoh T; Murota I; Yoshikai K; Yamada S; Yamamoto K
    Bioorg Med Chem; 2006 Jan; 14(1):98-108. PubMed ID: 16198578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.
    Mahindroo N; Wang CC; Liao CC; Huang CF; Lu IL; Lien TW; Peng YH; Huang WJ; Lin YT; Hsu MC; Lin CH; Tsai CH; Hsu JT; Chen X; Lyu PC; Chao YS; Wu SY; Hsieh HP
    J Med Chem; 2006 Feb; 49(3):1212-6. PubMed ID: 16451087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for differential activities of enantiomeric PPARĪ³ agonists: Binding of S35 to the alternate site.
    Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
    Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manipulation of reciprocal salt bridges at the heterodimerization interface alters the dimerization properties of mouse RXRalpha and PPARgamma1.
    Chan LS; Wells RA
    Biochem Biophys Res Commun; 2007 Jul; 358(4):1080-5. PubMed ID: 17521607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational screening of phthalate monoesters for binding to PPARgamma.
    Kaya T; Mohr SC; Waxman DJ; Vajda S
    Chem Res Toxicol; 2006 Aug; 19(8):999-1009. PubMed ID: 16918238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous nucleocytoplasmic shuttling underlies transcriptional activation of PPARgamma by FABP4.
    Ayers SD; Nedrow KL; Gillilan RE; Noy N
    Biochemistry; 2007 Jun; 46(23):6744-52. PubMed ID: 17516629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into PPARgamma from structures with endogenous and covalently bound ligands.
    Nettles KW
    Nat Struct Mol Biol; 2008 Sep; 15(9):893-5. PubMed ID: 18769464
    [No Abstract]   [Full Text] [Related]  

  • 20. Deoxyelephantopin inhibits cancer cell proliferation and functions as a selective partial agonist against PPARgamma.
    Zou G; Gao Z; Wang J; Zhang Y; Ding H; Huang J; Chen L; Guo Y; Jiang H; Shen X
    Biochem Pharmacol; 2008 Mar; 75(6):1381-92. PubMed ID: 18164690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.